NCT06486662View on ClinicalTrials.gov

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

February 19, 2025

Study Completion Date

February 19, 2025

Conditions
Allergic Asthma
Interventions
DRUG

OM-85-IN

Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN

DRUG

Placebo

Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo

Trial Locations (1)

30625

The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM, Hanover

Sponsors

Lead Sponsor

OM Pharma SA
All Listed Sponsors
lead

OM Pharma SA

INDUSTRY

NCT06486662 - A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients | Biotech Hunter | Biotech Hunter